Home » Market News » Healthcare » Northland Capital says Immupharma Plc “progressing well” this morning
Immupharma Plc

Northland Capital says Immupharma Plc “progressing well” this morning

  • ImmuPharma issued an update on its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential treatment of Lupus.
  • Key highlights included:
  • 200 patients were successfully recruited and randomised (dosed)
  • all patients in the study have passed the 9 months stage
  • 116 patients (58%) have completed the full 12 months of the study

 

Northland Capital analyst this morning said: “Lupuzor is progressing well through its pivotal Phase III trial. The drug continues to demonstrate a strong safety profile. The study is on track to report top line results in Q1-2018. Should Lupuzor successfully meet the trial endpoints, we estimate that ImmuPharma’s shares would significantly rerate to the upside.”

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.